Xenon Pharmaceuticals announces an investor webinar on non-opioid pain treatments targeting Kv7 and Nav1.7 programs on October 6, 2025.
Quiver AI Summary
Xenon Pharmaceuticals Inc., a biopharmaceutical company focused on neuroscience, has announced an investor webinar scheduled for October 6, 2025, from 11:30 AM to 12:30 PM Eastern Time. The webinar will provide an overview of Xenon's early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain. Attendees can submit questions during the live event or in advance via email. A live webcast will be available on the company's website and will be accessible for replay afterward. Xenon is advancing its drug discovery and clinical development efforts, including its lead molecule azetukalner, which is in Phase 3 trials for epilepsy and mood disorders, alongside other programs in initial stages for pain management.
Potential Positives
- Xenon Pharmaceuticals is showcasing its commitment to advancing innovative healthcare solutions by hosting an investor webinar focused on non-opioid pain treatments, which highlights its early-stage programs targeting Kv7 and Nav1.7.
- The webinar presents an opportunity for investors to engage with the company directly, demonstrating transparency and a proactive approach to investor relations.
- Xenon's lead molecule, azetukalner, is in Phase 3 clinical trials for multiple indications, indicating significant progress in clinical development and potential market impact.
Potential Negatives
- Investor interest may be limited, as the press release primarily announces a webinar rather than significant new data or advancements regarding product developments.
- The mention of early-stage programs could indicate that the company is still in preliminary phases of development, which may raise concerns about the timeline to commercialization and potential revenue generation.
- The press release offers no updates on financial performance or partnerships, leaving potential investors uncertain about the company's current position and future prospects.
FAQ
What is the focus of Xenon's upcoming investor webinar?
The webinar will focus on early-stage programs targeting Kv7 and Nav1.7 for non-opioid pain treatments.
When is the Xenon Pharmaceuticals investor webinar scheduled?
The webinar is scheduled for Monday, October 6, 2025, from 11:30 AM to 12:30 PM Eastern Time.
How can I attend the Xenon Pharmaceuticals webinar?
You can register for the webinar through the webcast link provided in the announcement.
Where can I find the replay of the Xenon webinar?
A replay of the webinar will be available in the “Investors” section of Xenon's website after the event.
What are the main therapeutic areas Xenon Pharmaceuticals is focused on?
Xenon is focused on drug discovery for pain treatment, epilepsy, major depressive disorder, and bipolar depression.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XENE Insider Trading Activity
$XENE insiders have traded $XENE stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:
- STEVEN GANNON sold 3 shares for an estimated $91
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XENE Hedge Fund Activity
We have seen 113 institutional investors add shares of $XENE stock to their portfolio, and 118 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,329,202 shares (+163.5%) to their portfolio in Q2 2025, for an estimated $104,204,022
- HOLOCENE ADVISORS, LP added 1,809,475 shares (+inf%) to their portfolio in Q2 2025, for an estimated $56,636,567
- WELLINGTON MANAGEMENT GROUP LLP removed 1,614,436 shares (-42.6%) from their portfolio in Q2 2025, for an estimated $50,531,846
- CAPITAL WORLD INVESTORS removed 1,568,978 shares (-70.5%) from their portfolio in Q2 2025, for an estimated $49,109,011
- STATE STREET CORP added 1,074,840 shares (+351.7%) to their portfolio in Q2 2025, for an estimated $33,642,492
- SAMLYN CAPITAL, LLC removed 1,016,381 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $31,812,725
- GEODE CAPITAL MANAGEMENT, LLC added 900,746 shares (+1294.2%) to their portfolio in Q2 2025, for an estimated $28,193,349
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XENE Analyst Ratings
Wall Street analysts have issued reports on $XENE in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 09/02/2025
- Wedbush issued a "Outperform" rating on 08/12/2025
- Chardan Capital issued a "Buy" rating on 08/12/2025
- Evercore ISI Group issued a "Outperform" rating on 05/14/2025
- Wells Fargo issued a "Overweight" rating on 05/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/13/2025
- Needham issued a "Buy" rating on 05/13/2025
To track analyst ratings and price targets for $XENE, check out Quiver Quantitative's $XENE forecast page.
$XENE Price Targets
Multiple analysts have issued price targets for $XENE recently. We have seen 9 analysts offer price targets for $XENE in the last 6 months, with a median target of $53.0.
Here are some recent targets:
- Benjamin Burnett from Wells Fargo set a target price of $48.0 on 09/03/2025
- Brian Abrahams from RBC Capital set a target price of $55.0 on 09/02/2025
- Rudy Li from Chardan Capital set a target price of $55.0 on 08/12/2025
- Laura Chico from Wedbush set a target price of $43.0 on 08/12/2025
- Cory Kasimov from Evercore ISI Group set a target price of $55.0 on 05/14/2025
- Douglas Tsao from HC Wainwright & Co. set a target price of $53.0 on 05/13/2025
- Serge Belanger from Needham set a target price of $55.0 on 05/13/2025
Full Release
VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain.
| Webinar: |
Developing Novel Non-Opioid Treatments for Pain: An Overview of Xenon’s Nav1.7 and Kv7 Programs
|
| Date : |
Monday, October 6, 2025
|
| Time : |
11:30 AM – 12:30 PM Eastern Time
|
| Webcast : |
Register here
|
|
Format
:
|
Questions may be submitted (via chat function) during the live webinar or submitted in advance via email to [email protected] . |
A live webcast of the webinar will be available on the “ Investors ” section of Xenon's website and posted for replay following the event. The above listed date and time are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X .
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media:
[email protected]
Investors:
[email protected]
